MarketPulse

immune response

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences' GLSI-100 Data Gets ASCO Platform; 70-80% Recurrence Reduction Shown

Greenwich LifeSciences' GLSI-100 breast cancer immunotherapy receives ASCO 2026 abstract acceptance, showing 70-80% recurrence reduction in Phase III trial.
GLSIGLSI-100FLAMINGO-01
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Posts Promising FLAMINGO-01 Data on Breast Cancer Immunotherapy

Greenwich LifeSciences reports significant immune response gains in Phase III FLAMINGO-01 trial for GLSI-100 breast cancer recurrence prevention, showing 70-80% recurrence reduction.
GLSIbreast cancerGLSI-100
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Shows Promise for Breast Cancer Prevention at AACR 2026

$GLSI's GLSI-100 immunotherapy demonstrates 70-80% recurrence reduction in Phase III trial data accepted for AACR presentation.
GLSIbreast cancerGLSI-100